Zu lab Publications
DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement
Mai, J, Li, X, Zhang, G, Huang, Y, Xu, R, Shen, Q, Lokesh, GL, Thiviyanathan, V, Chen, L, Liu, H, Zu, Y, Ma, X, Volk, DE, Gorenstein, DG, Ferrari, M & Shen, H 2018, Molecular Pharmaceutics, vol 15, no. 5, pp. 1814-1825. DOI: 10.1021/acs.molpharmaceut.7b01169
Updates in Polycythemia Vera
Nagrale, V, Olsen, RJ & Zu, Y 2018, . in C-CJ Chang & R Ohgami (eds), Precision Molecular Pathology of Myeloid Neoplasms. 1st edn, vol. 12, Springer, Switzerland, pp. 115-139. DOI: 10.1007/978-3-319-62146-3
A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells
Liu, H, Mai, J, Shen, J, Wolfram, J, Li, Z, Zhang, G, Xu, R, Li, Y, Mu, C, Zu, Y, Li, X, Lokesh, GL, Thiviyanathan, V, Volk, DE, Gorenstein, DG, Ferrari, M, Hu, Z & Shen, H 2018, Theranostics, vol 8, no. 1, pp. 31-44. DOI: 10.7150/thno.21342
Spin-Valve based magnetoresistive nanoparticle detector for applications in biosensing
Qiu, W, Chang, L, Liang, YC, Litvinov, J, Guo, J, Chen, YT, Vu, B, Kourentzi, K, Xu, S, Lee, TR, Zu, Y, Willson, RC & Litvinov, D 2017, Sensors and Actuators, A: Physical, vol 265, pp. 174-180. DOI: 10.1016/j.sna.2017.08.018
Diagnostic algorithm of common mature B-cell lymphomas by immunohistochemistry
Wang, HY & Zu, Y 2017, Archives of Pathology and Laboratory Medicine, vol 141, no. 9, pp. 1236-1246. DOI: 10.5858/arpa.2016-0521-RA
Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing
Wen, J, Tao, W, Hao, S & Zu, Y 2017, Journal of Hematology and Oncology, vol 10, no. 1, 119. DOI: 10.1186/s13045-017-0489-9
Ultrasensitive magnetic nanoparticle detector for biosensor applications
Liang, YC, Chang, L, Qiu, W, Kolhatkar, AG, Vu, B, Kourentzi, K, Lee, TR, Zu, Y, Willson, R & Litvinov, D 2017, Sensors (Switzerland), vol 17, no. 6, 1296. DOI: 10.3390/s17061296
Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy
Li, H, Yang, S, Yu, G, Shen, L, Fan, J, Xu, L, Zhang, H, Zhao, N, Zeng, Z, Hu, T, Wen, J & Zu, Y 2017, Theranostics, vol 7, no. 5, pp. 1204-1213. DOI: 10.7150/thno.17069
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
Xu-Monette, ZY, Li, L, Byrd, JC, Jabbar, KJ, Manyam, GC, De Winde, CM, Van Den Brand, M, Tzankov, A, Visco, C, Wang, J, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Winter, JN, Wang, M, Hagemeister, FB, Piris, MA, Van Krieken, JH, Medeiros, LJ, Li, Y, Van Spriel, AB & Young, KH 2016, Blood, vol 128, no. 26, pp. 3083-3100. DOI: 10.1182/blood-2016-05-715094
B7-H4 expression in ovarian serous carcinoma: a study of 306 cases
Liang, L, Jiang, Y, Chen, JS, Niu, N, Piao, J, Ning, J, Zu, Y, Zhang, J & Liu, J 2016, Human Pathology, vol 57, pp. 1-6. DOI: 10.1016/j.humpath.2016.06.011
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
Xia, Y, Xu-Monette, ZY, Tzankov, A, Li, X, Manyam, GC, Murty, V, Bhagat, G, Zhang, S, Pasqualucci, L, Visco, C, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Westin, J, Fowler, N, Miranda, RN, Ok, CY, Li, Y, Li, J, Medeiros, LJ & Young, KH 2016, Leukemia. DOI: 10.1038/leu.2016.243
Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Chen, Z, Shao, C, Wang, W, Zuo, Z, Mou, X, Hu, SJ, DiGiuseppe, JA, Zu, Y, Medeiros, LJ & Hu, S 2016, Leukemia. DOI: 10.1038/leu.2016.231
Overt leukemic phase: an unusual presentation of angioimmunoblastic lymphoma
Arora, K, Zhang, L, Xie, W, Baker, KR, Zu, Y & Hao, S 2016, Journal of Hematopathology, vol 9, no. 3, pp. 139-142. DOI: 10.1007/s12308-016-0278-3
Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma
Xu-Monette, ZY, Deng, Q, Manyam, GC, Tzankov, A, Li, L, Xia, Y, Wang, XX, Zou, D, Visco, C, Dybkær, K, Li, J, Zhang, L, Liang, H, Montes-Moreno, S, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Wang, SA, Miranda, RN, Piris, MA, Winter, JN, Medeiros, LJ, Li, Y & Young, KH 2016, Clinical Cancer Research, vol 22, no. 14, pp. 3593-3605. DOI: 10.1158/1078-0432.CCR-15-2296
RelA NF-kB subunit activation as a therapeutic target in diffuse large B-cell lymphoma
Zhang, M, Xu-Monette, ZY, Li, L, Manyam, GC, Visco, C, Tzankov, A, Wang, J, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Medeiros, LJ, Pham, LV & Young, KH 2016, Aging, vol 8, no. 12, pp. 3321-3340. DOI: 10.18632/aging.101121
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
Ye, Q, Xu-Monette, ZY, Tzankov, A, Deng, L, Wang, X, Manyam, GC, Visco, C, Montes-Moreno, S, Zhang, L, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, Medeiros, LJ, Hu, VDS & Young, KH 2016, Oncotarget, vol 7, no. 3, pp. 2401-2416. DOI: 10.18632/oncotarget.6262
p63 expression confers significantly better survival outcomes in highrisk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function
Xu-Monette, ZY, Zhang, S, Li, X, Manyam, GC, Wang, XX, Xia, Y, Visco, C, Tzankov, A, Zhang, L, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, HJ, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Medeiros, JL & Young, KH 2016, Aging, vol 8, no. 2, pp. 345-365.
SsDNA aptamer specifically targets and selectively delivers cytotoxic drug doxorubicin to HepG2 Cells
Yu, G, Li, H, Yang, S, Wen, J, Niu, J & Zu, Y 2016, PLoS ONE, vol 11, no. 1, e0147674. DOI: 10.1371/journal.pone.0147674